DekaBank Deutsche Girozentrale
KLRS

DekaBank Deutsche Girozentrale’s Kalaris Therapeutics KLRS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-935
Closed -$84K – 1447
2022
Q2 		$84K Hold
935
– – ﹤0.01% 1295
2022
Q1 		$156K Buy
935
+87
+10% +$17.4K ﹤0.01% 1241
2021
Q4 		$257K Buy
848
+22
+3% +$10.2K ﹤0.01% 1227
2021
Q3 		$473K Hold
826
– – ﹤0.01% 1059
2021
Q2 		$369K Hold
826
– – ﹤0.01% 1120
2021
Q1 		$422K Hold
826
– – ﹤0.01% 1058
2020
Q4 		$703K Buy
+826
New +$635K ﹤0.01% 950

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DekaBank Deutsche Girozentrale's KLRS Position: Q3 2022 in Review

DekaBank Deutsche Girozentrale sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 935 shares — an estimated $84K sold.

DekaBank Deutsche Girozentrale first reported a position in KLRS in Q4 2020 and held it in 7 quarters. The position peaked at $703K in Q4 2020. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 935 Kalaris Therapeutics shares in Q3 2022, an estimated $84K.
  • DekaBank Deutsche Girozentrale first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 7 quarters.
  • DekaBank Deutsche Girozentrale's Kalaris Therapeutics position peaked at $703K in Q4 2020.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2022, filed 2 Nov 2022.